CUL2抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: PC3 cells, Primary antibody: P10782(CUL2 Antibody) at dilution 1/440, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

The CUL2 antibody is a research tool designed to detect and study Cullin 2 (CUL2), a core component of the Cullin-RING E3 ubiquitin ligase (CRL) complexes. CUL2 functions as a scaffold protein in the CRL2 complex, which typically associates with substrate-recognition adaptors like the von Hippel-Lindau (VHL) tumor suppressor protein. This complex targets specific proteins, such as hypoxia-inducible factor 1α (HIF-1α), for ubiquitination and subsequent proteasomal degradation, playing a critical role in cellular oxygen sensing and tumor suppression. Dysregulation of CUL2 or its associated pathways is implicated in cancers, particularly renal cell carcinoma, where VHL mutations disrupt HIF-1α degradation, promoting angiogenesis and tumor growth.

CUL2 antibodies are widely used in molecular and cancer research to investigate protein expression, localization, and interactions. They enable techniques like Western blotting, immunohistochemistry (IHC), and co-immunoprecipitation (Co-IP) to explore CUL2's role in cellular processes, including cell cycle regulation, DNA repair, and response to hypoxia. Commercially available CUL2 antibodies vary in specificity, targeting different epitopes or post-translational modifications. Researchers must validate these antibodies for specific applications using appropriate controls, such as knockout cell lines, to ensure reliability. Understanding CUL2's function and regulation through antibody-based studies contributes to insights into disease mechanisms and potential therapeutic strategies targeting ubiquitin-proteasome pathways.